LAS VEGAS, Sept. 23, 2009 (GLOBE NEWSWIRE) -- It is again a time for brimming optimism for stem cell research with the American government returning to a position of support for the rich possibilities that may come from stem cell discovery. On the heels of an Executive Order repealing Bush-era policies toward stem cell research, signs of progress and potential are emerging, affirming a season of hope for the fruits of stem cell research. As stem cell discoveries return to the headlines, investors too have renewed interest and companies like BrainStorm (OTCBB:BCLI) are reporting its achievements to the market.
A report addressing one company's research using human bone marrow stem cells has been released. The report will explore the efforts of BrainStorm (OTCBB:BCLI) and is of interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).
View the report at: www.SmallCapSentinel.com/bcli
Over the past month, shares of BCLI have more than tripled, invigorated perhaps by the political climate initially and stoked by important news that the company has entered into a strategic agreement with Harlan Biotech Israel Ltd., a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company's innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease). Additionally, BrainStorm recently announced that it has entered into an agreement with Protein Production Services Ltd., a leading manufacturing contractor, in order to start Good Manufacturing Practice production of its stem cell therapeutic product. The clinical-grade product will be used in a pre-clinical safety trial for the company's innovative therapy for ALS.
BrainStorm (OTCBB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases.
Please register to receive more information on BCLI and other emerging public companies at:
www.SmallCapSentinel.com/register
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCapSentinel.com is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. In exchange for advertising and investor relations services related to BCLI over a twelve-month period, IMI is the beneficial owner of 625,000 shares of BCLI held by Emerging Markets Consulting (EMC), an investor relations consultant to BCLI which has been paid 1,250,000 total shares for twelve months of investor relations and related advertising. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.